default author photo

Robert Z. Orlowski

University of Texas at Houston - Department of Lymphoma and Myeloma

SCHOLARLY PAPERS

3

DOWNLOADS

208

TOTAL CITATIONS

0

Scholarly Papers (3)

Actions:
Email selected abstracts
1.

Outcome of Patients with Central Nervous System Multiple Myeloma (Cns-Mm) Treated with Cns-Directed Radiation Therapy

Number of pages: 35 Posted: 01 Jul 2024
Gohar Shahwar Manzar, Stephanie O. Dudzinski, Alison Yoder, Aaron Seo, Lewis F. Nasr, Hind Rafei, Melody Becnel, Krina K. Patel, Hans C. Lee, Gregory P. Kaufman, Mahmoud M. Gaballa, Jing Christine Ye, Neeraj Y. Saini, Sheeba K. Thomas, Behrang Amini, Robert Z. Orlowski, Bouthaina Dabaja, Chelsea Pinnix, Jillian Gunther, Susan Y. Wu and Penny Q. Fang
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Lymphoma and Myeloma, affiliation not provided to SSRN, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Radiation Oncology, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 76 (830,555)

Abstract:

Loading...

multiple myeloma, leptomeningeal disease, RT, CSI, craniospinal irradiation

2.

Safety and Efficacy of a New High-Dose Chemotherapy Regimen of Panobinostat, Gemcitabine, Busulfan and Melphalan for 1st or 2nd Salvage Autologous Stem Cell Transplant for Patients with Refractory/Relapsed or High-Risk Myeloma: Matched Pair Comparisons with Concurrent Control Cohorts

Number of pages: 33 Posted: 10 Aug 2023
Yago Nieto, Zixi Yang, Benigno C. Valdez, Roland Bassett, Suprateek Kundu, Melissa Barnett, Qaiser Bashir, Jeremy Ramdial, Jin Im, Partow Kebriaei, Uday Popat, Neeraj Y. Saini, Samer Srour, Jitesh Kawedia, Alison Gulbis, Rita Cool, Vi Doan, Terri Lynn Shigle, Whitney Wallis, Ruby Delgado, Sofia Qureshi, Hans C. Lee, Elisabet E. Manasanch, Robert Z. Orlowski, Krina K. Patel, Elizabeth J. Shpall, Borje S. Andersson and Muzaffar Qazilbash
University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center and University of Texas at Houston - MD Anderson Cancer Center
Downloads 72 (860,052)

Abstract:

Loading...

Myeloma, autologous stem-cell transplant, high-dose chemotherapy, phase 2 trial, matched pair comparison

3.

Single Cell Clonotypic and Transcriptional Evolution of Multiple Myeloma Precursor Disease

Number of pages: 68 Posted: 09 Nov 2022
Minghao Dang, Guangchun Han, Hans C. Lee, Krina K. Patel, Sheeba K. Thomas, Dapeng Hao, Yanshuo Chu, Melody Becnel, Donna M. Weber, Pei Lin, Zuzana Lutter-Berka, David Berrios Nolasco, Xingzhi Song, Jianhua Zhang, P. Andrew Futreal, Yurany Moreno Rueda, David Symer, Michael Green, Cristhiam Rojas Hernandez, Michael Kroll, Vashir Afshar-Kharghan, Libere J. Ndacayisaba, Peter Kuhn, Sattva S. Neelapu, Robert Z. Orlowski, Linghua Wang and Elisabet E. Manasanch
University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Hematopathology, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Southern California - Keck School of Medicine, University of Southern California - Keck School of Medicine, University of Southern California - Keck School of Medicine, University of Southern California, University of Southern California, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Genomic Medicine and University of Texas at Houston - Department of Lymphoma and Myeloma
Downloads 60 (961,006)

Abstract:

Loading...

single-cell RNA sequencing (scRNAseq), multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), single-cell B cell receptor sequencing (scBCR-seq), plasma cells (PCs), intra-tumoral heterogeneity (ITH), tumor microenvironment (TME), hyperdiploid (HY), non-hyperdiploid (non-HY)